NCT00924807 2018-12-11Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate CancerBeth Israel Medical CenterPhase 1/2 Terminated4 enrolled 4 charts
NCT00414388 2014-04-07Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate CancerOncology Specialists, S.C.Phase 1/2 Completed22 enrolled 8 charts